3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lung Neoplasms
12
Ovarian Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Fallopian Tube Neoplasms
6
Urinary Bladder Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Hepatocellular
5
Squamous Cell Carcinoma of Head and Neck
4
Pancreatic Neoplasms
4
Carcinoma, Renal Cell
4
Neoplasm Metastasis
3
Mouth Neoplasms
3
Melanoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Glioblastoma
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Thyroid Neoplasms
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Oropharyngeal Neoplasms
2
Nasopharyngeal Carcinoma
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Lymphoid Interstitial Pneumonia
2
Laryngeal Neoplasms
2
Interventions
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
balstilimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Disulfides
×
90 days
×
Clear all
NCT04668300
2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
75 enrolled